link
Bookmarks
Bisphosphonates: Complications
Cheryl A. Petersilge, MD, MBA; B.J. Manaster, MD, PhD, FACR
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe
0
4
20
0

KEY FACTS

  • Imaging

    • Pathology

      • Clinical Issues

        Selected References

        1. Probyn L et al: Bilateral atypical femoral fractures: how much symmetry is there on imaging? Skeletal Radiol. 44(11):1579-84, 2015
        2. Dell RM et al: Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 27(12):2544-50, 2012
        3. Png MA et al: Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. AJR Am J Roentgenol. 198(4):869-77, 2012
        4. Sidhu HS et al: Imaging features of therapeutic drug-induced musculoskeletal abnormalities. Radiographics. 32(1):105-27, 2012
        5. Vigorita VJ et al: Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol. 41(7):861-5, 2012
        6. Reid IR: Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol. 40(9):1191-6, 2011
        7. Rosenberg ZS et al: Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. AJR Am J Roentgenol. 197(4):954-60, 2011
        8. Rogers LF et al: FDA statement on relationship between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures: a considered opinion. AJR Am J Roentgenol. 195(3):563-6, 2010
        9. Gupta S et al: Zoledronic acid induced osteonecrosis of tibia and femur. Indian J Cancer. 46(3):249-50, 2009
        10. Papapetrou PD: Bisphosphonate-associated adverse events. Hormones (Athens). 8(2):96-110, 2009
        11. Schilcher J et al: Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 80(4):413-5, 2009
        12. Carey JJ et al: Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med. 75(12):871-9, 2008
        13. Kwek EB et al: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 39(2):224-31, 2008
        14. Lenart BA et al: Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 358(12):1304-6, 2008
        15. Neviaser AS et al: Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 22(5):346-50, 2008
        Related Anatomy
        Loading...
        Related Differential Diagnoses
        Loading...
        References
        Tables

        Tables

        KEY FACTS

        • Imaging

          • Pathology

            • Clinical Issues

              Selected References

              1. Probyn L et al: Bilateral atypical femoral fractures: how much symmetry is there on imaging? Skeletal Radiol. 44(11):1579-84, 2015
              2. Dell RM et al: Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 27(12):2544-50, 2012
              3. Png MA et al: Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. AJR Am J Roentgenol. 198(4):869-77, 2012
              4. Sidhu HS et al: Imaging features of therapeutic drug-induced musculoskeletal abnormalities. Radiographics. 32(1):105-27, 2012
              5. Vigorita VJ et al: Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol. 41(7):861-5, 2012
              6. Reid IR: Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol. 40(9):1191-6, 2011
              7. Rosenberg ZS et al: Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. AJR Am J Roentgenol. 197(4):954-60, 2011
              8. Rogers LF et al: FDA statement on relationship between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures: a considered opinion. AJR Am J Roentgenol. 195(3):563-6, 2010
              9. Gupta S et al: Zoledronic acid induced osteonecrosis of tibia and femur. Indian J Cancer. 46(3):249-50, 2009
              10. Papapetrou PD: Bisphosphonate-associated adverse events. Hormones (Athens). 8(2):96-110, 2009
              11. Schilcher J et al: Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 80(4):413-5, 2009
              12. Carey JJ et al: Bisphosphonates and osteonecrosis of the jaw: innocent association or significant risk? Cleve Clin J Med. 75(12):871-9, 2008
              13. Kwek EB et al: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 39(2):224-31, 2008
              14. Lenart BA et al: Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 358(12):1304-6, 2008
              15. Neviaser AS et al: Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 22(5):346-50, 2008